Option Care Health Inc (OPCH) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Option Care Health Inc stock $30.88, price $31.65, that is 2.4% below the price, quality 68 out of 100. Rating: fairly valued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range $19.52 – $36.59 · fair‑value band $19.20 – $39.67 · the $31.65 price screens above the $30.88 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.
Follow Option Care Health in your weekly email
Every Wednesday you see whether Option Care Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Option Care Health, Inc. offers home and alternate site infusion services in the United States.
Show moreShow less
The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.
It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services.
The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. The company is headquartered in Bannockburn, Illinois.
Stock analysis
Option Care Health Inc (OPCH) currently trades at $31.65, while our model-based Fair Value estimate is $30.88, so the stock looks roughly fairly valued today (gap 2.5%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $38.19 per share, and 12 of the 22 models we run sit above the $31.65 price.
Bear case: the Economic Profit group reads lowest at $16.98, and 10 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $19.20 (bear) to $39.67 (bull), the price of $31.65 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Option Care Health Inc reported revenue of $5.6B in FY2025 versus $3.4B in FY2021, a compound +13.2%/yr. Reported net income was $208M in FY2025, compounding +10.4%/yr from FY2021.
Key figures
Market cap $4.9B Mid · P/E ratio 22.8 · P/S ratio 0.86 · EPS (TTM) $1.39 · Net margin 3.7% · Return on equity 16.0% · Return on assets (EBIT) 8.6% (5-year average) · Operating margin 6.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 14% below its 52-week high and 62% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −2%, OPCH screens richer than that median.
Fair Value models
Bear$19.20Fair Value $30.88Bull$39.67
Price $31.65 · Downside -2.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($1.19 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, no officer or director bought or sold shares on the open market.
BuyTimothy P SullivanDirector24,154 shares at $20.69$499,746May 7, 2026
BuyHarry M Jansen Kraemer JrDirector36,610 shares at $21.41$783,820May 4, 2026
BuyJohn Charles RademacherChief Executive Officer, Director12,500 shares at $21.18$264,750May 4, 2026
BuyMeenal SethnaChief Financial Officer16,225 shares at $20.16$327,096May 4, 2026
SaleMichael BavaroChief Human Resources Officer6,000 shares at $33.00$198,000Feb 27, 2026
SaleR Carter PateDirector30,287 shares at $32.05$970,698Feb 27, 2026
Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.89/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+13.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
Start year 2020 (pandemic). Over 10 years: +19.1% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+21.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+21.5%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 6%
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +9.1% a year for the price and +2.4% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Option Care Health draws its main strength from scale as the largest independent provider of complex home and alternate-site infusions, while its main weak point remains thin evidence of a durable moat beyond moderate organization capital and pricing power.
Main risk: New layers of coordination from the McKesson partnership could slow execution and hinder growth in lower-cost home infusion settings.
Option Care Health delivers home and alternate-site infusions for complex therapies to hundreds of thousands of patients nationwide as the largest independent provider in its field. The deal brings McKesson in as a minority strategic partner while the company stays separate with its own leadership and operations. Will the added expertise mainly speed growth in lower-cost settings or create new layers of coordination that slow execution?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 233 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside−2.4% · Below median
Profitability
Return on equity (12 months)16.0% · Top 25%
Return on assets6.0% · Above median
Net margin (12 months)3.7% · Below median
Operating margin (12 months)6.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)4.1% · Below median
Balance sheet
Debt / equity0.87× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)22.8× · Pricier than median
P/B3.72× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)0.86× · Cheapest 25%
Price / free cash flow (fiscal year)22.7× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Option Care Health Inc Fair Value". https://www.fairvalue-calculator.com/stock/OPCH
Frequently asked questions
Is Option Care Health Inc (OPCH) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $30.88 versus a price of $31.65, about 2% lower (fairly valued).
What is the fair value of OPCH?
Our model-based fair value for Option Care Health Inc is $30.88 (as of Nov 7, 2026), built from audited fundamentals. The current price: $31.65.
What is the quality score of OPCH?
Option Care Health Inc has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Option Care Health Inc (OPCH)?
Our model-based price target is the fair value of $30.88 (as of Nov 7, 2026) from 22 valuation models. Cautious scenario $19.20, optimistic scenario $39.67. It is a calculation from audited fundamentals, not an analyst target.
What is the Option Care Health Inc stock forecast for 2026?
Our models put fair value at $30.88, about 2% lower versus a price of $31.65 (fairly valued). Cautious scenario $19.20, optimistic scenario $39.67. The calculation is refreshed regularly with new filings.
What is the revenue of Option Care Health Inc (OPCH)?
Option Care Health Inc reported trailing-twelve-month revenue of about $5.8B (latest available figure, as of Nov 7, 2026).
What growth is priced into Option Care Health Inc (OPCH)?
For today's price to be fair in a discounted-cash-flow model, Option Care Health Inc would have to grow free cash flow by +11.7 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.3 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of OPCH use?
Our models discount Option Care Health Inc at 8.5 %: a base by market capitalisation (mid), damped by beta 0.46, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Option Care Health Inc that is +11.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Option Care Health Inc (OPCH) delivered so far?
Over the past 5 years revenue at Option Care Health Inc grew +13.3 % a year. The price currently implies free-cash-flow growth of +11.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Option Care Health Inc (OPCH) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Option Care Health Inc (+11.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Option Care Health Inc (OPCH)?
The free-cash-flow yield on the price is 4.40 %: that much free cash flow Option Care Health Inc produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Option Care Health Inc (OPCH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Option Care Health Inc it is $30.88 per share (as of Nov 7, 2026), against a price of $31.65. It is the blended result of 22 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Option Care Health Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, OPCH trades above its calculated fair value: price $31.65, fair value $30.88, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OPCH?
No. The price is what the market pays today ($31.65); the fair value is what the company's own numbers justify ($30.88). For Option Care Health Inc the two are $0.7700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Option Care Health Inc worth?
The market values Option Care Health Inc at about $4.9B (market capitalisation, as of Nov 7, 2026). Per share that is $31.65; our models calculate a fair value of $30.88 per share.
What do the bullish and bearish scenarios say about OPCH?
Our models span a range for Option Care Health Inc: cautious scenario $19.20, base $30.88, optimistic $39.67 per share (as of Nov 7, 2026, price $31.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of OPCH?
Option Care Health Inc trades at a price-to-earnings ratio of 22.8 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $30.88 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings: 25.1. Other multiples: PEG 1.5, P/B 3.7, P/S 0.9, EV/EBITDA 14.2.
What is the PEG ratio of OPCH?
The PEG ratio of Option Care Health Inc is 1.51 (P/E divided by earnings growth, as of Nov 7, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Option Care Health Inc (OPCH)?
Balance-sheet figures for Option Care Health Inc (as of Nov 7, 2026): return on equity 16.0%, debt of 0.87 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is OPCH from its 52-week high?
Option Care Health Inc trades at $31.65, about 14% below its 52-week high of $36.59 and 62% above the low of $19.52 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $30.88 is for.
Which stocks are comparable to Option Care Health Inc?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Option Care Health Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $31.65, calculated fair value $30.88 (−2%), Quality Score 68/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OPCH calculated?
We run Option Care Health Inc through 22 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $30.88 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Option Care Health Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Option Care Health Inc (OPCH)?
The closing price on Nov 6, 2026 was $31.65. Our model-based fair value is $30.88, about 2% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Option Care Health Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($19.20 to $39.67) leaves room in how you read the outcome.
Key figures of Option Care Health Inc
How large is the market capitalisation of Option Care Health Inc (OPCH)?
The market capitalisation of Option Care Health Inc is $4.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Option Care Health Inc (OPCH)?
The price-to-sales ratio of Option Care Health Inc is 0.86 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Option Care Health Inc (OPCH)?
Earnings per share at Option Care Health Inc are $1.39 (price ÷ EPS = P/E 22.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Option Care Health Inc (OPCH)?
The net margin of Option Care Health Inc is 3.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Option Care Health Inc (OPCH)?
The return on equity (ROE) of Option Care Health Inc is 16.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Option Care Health Inc (OPCH)?
On an EBIT basis the return on assets of Option Care Health Inc is 8.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Option Care Health Inc (OPCH)?
The operating margin of Option Care Health Inc is 6.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Option Care Health Inc (OPCH)?
Revenue at Option Care Health Inc is growing +4.1% versus a year earlier (3y avg +12.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Option Care Health Inc (OPCH)?
Earnings per share at Option Care Health Inc are growing +18.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Option Care Health Inc (OPCH) hold?
Option Care Health Inc holds more cash than debt, $233M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Option Care Health Inc in the live analysis
One click puts Option Care Health Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026